Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis

Infection with Mycobacterium tuberculosis is controlled by an efficacious immune response in about 90% of infected individuals who do not develop disease. Although essential mediators of protection, e.g., interferon-γ, have been identified, these factors are insufficient to predict the outcome of M. tuberculosis infection. As a first step to determine additional biomarkers, we compared gene expression profiles of peripheral blood mononuclear cells from tuberculosis patients and M. tuberculosis-infected healthy donors by microarray analysis. Differentially expressed candidate genes were predominantly derived from monocytes and comprised molecules involved in the antimicrobial defense, inflammation, chemotaxis, and intracellular trafficking. We verified differential expression for alpha-defensin 1, alpha-defensin 4, lactoferrin, Fcγ receptor 1A (cluster of differentiation 64 [CD64]), bactericidal permeability-increasing protein, and formyl peptide receptor 1 by quantitative polymerase chain reaction analysis. Moreover, we identified increased protein expression of CD64 on monocytes from tuberculosis patients. Candidate biomarkers were then assessed for optimal study group discrimination. Using a linear discriminant analysis, a minimal group of genes comprising lactoferrin, CD64, and the Ras-associated GTPase 33A was sufficient for classification of (1) tuberculosis patients, (2) M. tuberculosis-infected healthy donors, and (3) noninfected healthy donors.

[1]  A. Kalita,et al.  Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. , 2004, The Journal of infectious diseases.

[2]  J. Flynn,et al.  Immunology of tuberculosis. , 2003, Annual review of immunology.

[3]  A. Krensky,et al.  T-cell release of granulysin contributes to host defense in leprosy , 2001, Nature Medicine.

[4]  D G Altman,et al.  What do we mean by validating a prognostic model? , 2000, Statistics in medicine.

[5]  A. Ziegler,et al.  Deconfounding microarray analysis - independent measurements of cell type proportions used in a regression model to resolve tissue heterogeneity bias. , 2006, Methods of information in medicine.

[6]  Philip M Murphy,et al.  Formyl-peptide receptors revisited. , 2002, Trends in immunology.

[7]  L. Ting,et al.  Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1. , 1999, Journal of immunology.

[8]  S. S. Young,et al.  Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment , 1993 .

[9]  C. Rubel,et al.  N-Formyl-Methionyl-Leucyl-Phenylalanine Inhibits both Gamma Interferon- and Interleukin-10-Induced Expression of FcγRI on Human Monocytes , 2001, Clinical Diagnostic Laboratory Immunology.

[10]  S. Kaufmann,et al.  Correction of the Iron Overload Defect in β-2-Microglobulin Knockout Mice by Lactoferrin Abolishes Their Increased Susceptibility to Tuberculosis , 2002, The Journal of experimental medicine.

[11]  O. Conneely,et al.  Lactoferrin and host defense. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[12]  Marino Zerial,et al.  Rab proteins as membrane organizers , 2001, Nature Reviews Molecular Cell Biology.

[13]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[14]  T. van der Poll,et al.  Serum concentrations of lipopolysaccharide activity-modulating proteins during tuberculosis. , 1998, The Journal of infectious diseases.

[15]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[16]  R. Snyderman,et al.  Chemoattractant receptors on phagocytic cells. , 1984, Annual review of immunology.

[17]  N. Hibler,et al.  Arrest of Mycobacterial Phagosome Maturation Is Caused by a Block in Vesicle Fusion between Stages Controlled by rab5 and rab7* , 1997, The Journal of Biological Chemistry.

[18]  R. Modlin,et al.  Control of Mycobacterium tuberculosis through mammalian Toll-like receptors. , 2002, Current opinion in immunology.

[19]  Bernhard Hemmer,et al.  A point mutation in PTPRC is associated with the development of multiple sclerosis , 2000, Nature Genetics.

[20]  Stefan H E Kaufmann,et al.  Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis , 2005, Nature Medicine.

[21]  J. V. D. van de Winkel,et al.  Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. , 1993, Immunology today.

[22]  A. Ziegler,et al.  Ras-associated small GTPase 33A, a novel T cell factor, is down-regulated in patients with tuberculosis. , 2005, The Journal of infectious diseases.

[23]  Y. H. Chan Biostatistics 303. Discriminant analysis. , 2005, Singapore medical journal.

[24]  Javed Khan,et al.  Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. , 2003, Human molecular genetics.

[25]  C. Figdor,et al.  IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. , 1992, Journal of immunology.

[26]  S. Kaufmann,et al.  How can immunology contribute to the control of tuberculosis? , 2001, Nature Reviews Immunology.

[27]  C. Nathan,et al.  Reactive nitrogen intermediates and the pathogenesis of Salmonella and mycobacteria. , 2000, Current opinion in microbiology.

[28]  G. Vanham,et al.  Generalized immune activation in pulmonary tuberculosis: co‐activation with HIV infection , 1996, Clinical and experimental immunology.

[29]  G. Khuller,et al.  Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. , 2000, The European respiratory journal.

[30]  J. Flynn,et al.  Induction of M3-Restricted Cytotoxic T Lymphocyte Responses by N-Formylated Peptides Derived from Mycobacterium tuberculosis , 2001, The Journal of experimental medicine.